logo
Share SHARE
FONT-SIZE Plus   Neg

Sify Technologies Q4 IFRS Loss Narrows - Quick Facts

Sify Technologies Ltd. (SIFY) posted fourth-quarter IFRS net loss of INR 60 million versus loss of INR 108 million last year.

Revenue for the quarter climbed to INR 1.86 billion from INR 1.71 billion in the prior year.

MP Vijay Kumar, chief financial officer, said, "Our continued focus onoptimising cost, while retaining our growth momentum, is yielding positive results. Operating cash flow continues to be positive and gross margins have remained steady, in spite of continuing pricing pressure in the market. As a result, we are seeing a consistent contribution to our EBITDA from both existing and new value-added services we have introduced."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of International Consolidated Airlines Group S.A. were gaining around 3 percent in London trading after the airline reported Friday higher profit in its second quarter, benefited by higher passenger revenues, despite weak cargo revenues. The company now expects low double digit percentage growth in pre-exceptional operating profit in 2016. Swiss banking giant UBS Group AG reported Friday a 14 percent decline in second quarter profit with weakness in net interest income. Looking ahead, the company said the difficult conditions continue to persist, yet the firm is well positioned to benefit from even a moderate improvement in conditions. UBS shares were gaining around 3 percent in the morning trading in Zurich. We are well into the third quarter and past the middle of the year and it is time to take stock of regulatory decisions awaiting some biotech stocks in August. Despite the uncertain macroeconomic environment, the markets have run up, with the S&P 500 Index making new highs session after session. Valuation concerns may keep traders at bay. However, the biotech space is a different cup of tea.
comments powered by Disqus
Follow RTT